Total Payments
$20,695
2024 Payments
$2,324
Companies
46
Transactions
850
Medicare Patients
19,599
Medicare Billing
$2.3M
Payment Breakdown by Category
Food & Beverage$18,555 (89.7%)
Travel$1,406 (6.8%)
Education$734.06 (3.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $18,555 | 817 | 89.7% |
| Travel and Lodging | $1,406 | 7 | 6.8% |
| Education | $734.06 | 26 | 3.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $2,287 | 78 | $0 (2024) |
| Medtronic, Inc. | $1,949 | 16 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $1,475 | 92 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,436 | 61 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,312 | 61 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,115 | 52 | $0 (2022) |
| Gilead Sciences, Inc. | $1,019 | 81 | $0 (2019) |
| Boston Scientific Corporation | $960.74 | 19 | $0 (2024) |
| Medtronic Vascular, Inc. | $837.03 | 13 | $0 (2020) |
| PFIZER INC. | $812.44 | 43 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,324 | 76 | AstraZeneca Pharmaceuticals LP ($277.91) |
| 2023 | $2,304 | 76 | Novartis Pharmaceuticals Corporation ($369.54) |
| 2022 | $4,051 | 95 | Medtronic, Inc. ($1,625) |
| 2021 | $1,972 | 87 | BOSTON SCIENTIFIC CORPORATION ($390.44) |
| 2020 | $1,743 | 81 | Actelion Pharmaceuticals US, Inc. ($315.80) |
| 2019 | $2,252 | 124 | Janssen Pharmaceuticals, Inc ($391.79) |
| 2018 | $3,286 | 165 | Medtronic Vascular, Inc. ($422.42) |
| 2017 | $2,764 | 146 | Gilead Sciences Inc ($426.65) |
All Payment Transactions
850 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $26.85 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $32.72 | General |
| Category: DIABETES | ||||||
| 11/27/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $39.73 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 11/23/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/16/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $4.17 | General |
| Category: Not Applicable | ||||||
| 11/15/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: Not Applicable | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $26.37 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/08/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug), Kerendia | Food and Beverage | In-kind items and services | $30.40 | General |
| Category: Cardio-pulmonary | ||||||
| 11/06/2024 | ATRICURE, INC. | ATRICLIP LAA EXCLUSION SYSTEM (Device) | Food and Beverage | In-kind items and services | $157.04 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/25/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $25.63 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/22/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $29.12 | General |
| Category: Cardiology | ||||||
| 10/19/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/16/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: Diabetes | ||||||
| 10/11/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $24.55 | General |
| Category: Diabetes | ||||||
| 09/27/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $24.68 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/26/2024 | Edwards Lifesciences Corporation | Edwards SAPIEN 3 Ultra Transcatheter Heart Valve (Device) | Food and Beverage | In-kind items and services | $84.43 | General |
| Category: Transcatheter Heart Valves | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/20/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $22.05 | General |
| Category: Cardiology | ||||||
| 09/18/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $31.06 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/13/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $26.66 | General |
| Category: Not Applicable | ||||||
| 09/11/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $25.44 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 09/06/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $26.73 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/21/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $30.01 | General |
| Category: Cardiology | ||||||
| 08/14/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $27.99 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/09/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $12.79 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 5,033 | 6,890 | $1.8M | $559,001 |
| 2022 | 25 | 4,794 | 6,611 | $1.8M | $563,266 |
| 2021 | 29 | 4,933 | 6,907 | $1.7M | $607,130 |
| 2020 | 30 | 4,839 | 6,672 | $1.6M | $542,238 |
Total Patients
19,599
Total Services
27,080
Medicare Billing
$2.3M
Procedure Codes
111
All Medicare Procedures & Services
111 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 812 | 1,810 | $348,540 | $193,794 | 55.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 514 | 518 | $362,600 | $98,353 | 27.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 231 | 598 | $149,500 | $42,924 | 28.7% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 184 | 184 | $124,200 | $42,150 | 33.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 266 | 318 | $82,680 | $33,943 | 41.1% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 156 | 156 | $62,400 | $30,566 | 49.0% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 270 | 270 | $52,650 | $21,887 | 41.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 213 | 250 | $32,540 | $20,282 | 62.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 272 | 281 | $193,050 | $16,483 | 8.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 103 | 103 | $30,900 | $12,242 | 39.6% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 1,052 | 1,331 | $77,025 | $9,100 | 11.8% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 112 | 112 | $12,320 | $8,491 | 68.9% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 27 | 29 | $120,263 | $6,436 | 5.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 446 | 489 | $36,675 | $6,229 | 17.0% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 82 | 82 | $28,700 | $5,240 | 18.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 125 | 125 | $7,500 | $4,643 | 61.9% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 40 | 70 | $7,000 | $2,183 | 31.2% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 26 | 34 | $3,740 | $1,702 | 45.5% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 15 | 25 | $3,250 | $594.48 | 18.3% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 19 | 22 | $6,448 | $485.10 | 7.5% |
| 90756 | Influenza vaccine, quadrivalent derived from cell cultures | Office | 2023 | 12 | 12 | $720.00 | $380.64 | 52.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 19 | 34 | $5,100 | $352.25 | 6.9% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 26 | 26 | $6,741 | $285.20 | 4.2% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Facility | 2023 | 11 | 11 | $5,500 | $255.31 | 4.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 831 | 1,876 | $354,100 | $199,054 | 56.2% |
About Dr. Kwan Chen, MD
Dr. Kwan Chen, MD is a Interventional Cardiology healthcare provider based in Fremont, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1619928025.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kwan Chen, MD has received a total of $20,695 in payments from pharmaceutical and medical device companies, with $2,324 received in 2024. These payments were reported across 850 transactions from 46 companies. The most common payment nature is "Food and Beverage" ($18,555).
As a Medicare-enrolled provider, Chen has provided services to 19,599 Medicare beneficiaries, totaling 27,080 services with total Medicare billing of $2.3M. Data is available for 4 years (2020–2023), covering 111 distinct procedure/service records.
Ad
Practice Information
- Specialty Interventional Cardiology
- Location Fremont, CA
- Active Since 05/12/2006
- Last Updated 04/22/2022
- Taxonomy Code 207RI0011X
- Entity Type Individual
- NPI Number 1619928025
Products in Payments
- MICRA (Device) $1,725
- ELIQUIS (Drug) $1,667
- XARELTO (Drug) $1,360
- OPSUMIT (Drug) $1,125
- ENTRESTO (Drug) $970.73
- UPTRAVI (Drug) $780.52
- Adempas (Drug) $553.25
- FARXIGA (Drug) $544.10
- JARDIANCE (Drug) $521.18
- VERQUVO (Drug) $520.63
- Vascepa (Drug) $479.13
- LEQVIO (Drug) $464.98
- BRILINTA (Drug) $441.17
- WATCHMAN (Device) $431.17
- Repatha (Biological) $387.05
- Letairis (Drug) $332.34
- LifeVest (Device) $330.86
- Azure (Device) $303.91
- Rybelsus (Drug) $292.16
- Ozempic (Drug) $291.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Interventional Cardiology Doctors in Fremont
Steven Degalan, M.d, M.D
Interventional Cardiology — Payments: $17,620
Interventional Cardiology $17,620
Rohit Sehgal, Md, MD
Interventional Cardiology — Payments: $11,215
Interventional Cardiology $11,215
Terence Lin, Md, MD
Interventional Cardiology — Payments: $5,372
Interventional Cardiology $5,372
Dr. Nowwar Mustafa, Md, MD
Interventional Cardiology — Payments: $2,730
Interventional Cardiology $2,730